Table 1.
Inputs for the US and Japan cost models
| Input parameter | US model value | Japan model valueb |
|---|---|---|
| Drug acquisition costsa,c | ||
| Pemetrexed | $5.80 per mg | ¥360.45/US$3.69 per mg |
| Carboplatin | $0.07 per mg | ¥52.23/US$0.53 per mg |
| Paclitaxel | $0.16 per mg | ¥154.74/US$1.58 per mg |
| Bevacizumab | $6.21 per mg | ¥433.78/US$4.44 per mg |
| Docetaxel | $9.16 per mg | ¥539.55/US$5.53 per mg |
| Erlotinib | $1.28 per mg | ¥68.98/US$0.71 per mg |
| Premedicationsa,c | ||
| Folic acid | $0.01 per 800-µg tablet | ¥9.60/US$0.10 per 5-mg tablet |
| Vitamin B-12 | $2.44 per 1000-µg/mL injection | ¥100.00/US$1.02 per 1000-µg/mL injection |
| Dexamethasone | $0.10 per 4-mg tablet | ¥98.00/US$1.00 per 4-mg injection |
| Diphenhydramine | $2.75 per 50-mg/mL | ¥112.00/US$1.15 per 50-mg/mL IV |
| Cimetidine | $3.26 per 300-mg IV | ¥112.00/US$1.15 per 300-mg IV |
| Ranitidine | $5.42 per 50-mg IV | ¥88.00/US$0.90 per 50-mg IV |
| Famotidine | $0.74 per 20-mg IV | ¥92.00/US$0.94 per 20-mg IV |
| Infusion costsd | ||
| Initial infusion (up to 1 h, over 500 mL) | $230.50 | ¥7250.00/US$74.26 |
| Additional hour | $39.13 | Not in model |
| Subsequent infusion | $74.69 | Not in model |
| Maintenance infusion (up to 1 h, over 500 mL) | $230.50 | ¥7250.00/US$74.26 |
| G-CSFa,c | ||
| Neulasta | $3906.04 per 6 mg/0.6 mL injection | ¥495,620.00/US$5076.51 per 6 mg/0.6 mL injection |
| Filgastrim | Not included in model | ¥24,781.00/US$253.83 per 300-µg injection |
| Transfusionsd,e | ||
| Transfusion administration cost | $260.44 | ¥500.00/US$5.12 |
| Platelet cost per unit | $91.61 | ¥7546.00/US$77.29 |
| Fresh frozen plasma | $72.23 | ¥8706.00/US$89.17 |
| Packed red blood cells | $151.79 | ¥8169.00/US$83.67 |
| ESAsa,e | ||
| Procrit | $0.02 per unit | ¥1.24/US$0.01 per IU |
| Epogen | $0.14 per unit | ¥1.24/US$0.01 per IU |
| Aranesp | $6.43 per µg | ¥176.89/US$1.81 per µg |
| Grade 3–4 toxicity costs (mean costs)f,g | ||
| Febrile neutropenia (ICD-9 288.00) | $12,006 | ¥80,688.90/US$826.48 |
| Fatigue (ICD-9 780.79) | $6304 | ¥28,972.81/US$296.76 |
| Hypertension (ICD-9 401.00) | $6095 | ¥28,833.70/US$295.34 |
| Thrombosis/thrombus/embolism (ICD-9 444.00) | $25,729 | ¥87.00/US$0.89 |
| Any hemorrhagic events (ICD-9 578.90) | $9420 | ¥0.00/US$0.00 |
| Neuropathy, sensory (ICD-9 357.60) | $8914 | ¥29,363.75/US$300.77 |
| Nausea (ICD-9 787.02) | $5592 | ¥0.00/US$0.00 |
| Vomiting (ICD-9 787.03) | $4499 | ¥3.36/US$0.03 |
| Anemia (ICD-9 285.30) | $6142 | ¥7576.10/US$77.60 |
| Neutropenia (ICD-9 288.00) | $12,006 | ¥20,650.83/$US211.52 |
| Thrombocytopenia (ICD-9 287.31) | $16,488 | ¥3773.00/US$38.65 |
| Drugs used to manage grade 3–4 toxicityc | ||
| G-CSF (Filgrastim) | Drugs for toxicity management not included in US model for costs of toxicity | ¥24,781.00/US$253.83 per 300-µg injection |
| Levofloxacin | ¥475.30/US$4.87 per 500-mg tablet | |
| Sodium ferrous citrate | ¥5.60/US$0.06 per 50-mg tablet | |
| Domperidone | ¥5.60/US$0.06 per 10-mg tablet | |
| Tranexamic acid | ¥58.00/US$0.59 per 250-mg injection | |
| Goshajinkigan | ¥11.80/$0.12 per 1-g granule | |
| Valsartan | ¥61.40/$0.63 per 40-mg tablet | |
| Candesartan cilexetil | ¥72.30/$US0.74 per 4-mg tablet | |
| Daikenchuto | ¥9.70/US$0.10 per 1-g granule | |
CPT Current Procedural Terminology, ESAs Erythropoiesis-stimulating agents, G-CSF Growth colony stimulating factors, HCPCS Healthcare Common Procedure Coding System, ICD-9 International Classification of Diseases 9th Revision, IV Intravenous
aUS Lowest wholesale acquisition cost from Truven Health Analytics (2013)
bCosts based on 2013 exchange rate monthly average of 97.63 Yen per one dollar [20]
cJapan costs from Hokenyaku Jiten Plus, 2013 April edition, Yakugyou Kenkyuu Kai, 2013
dCenters for Medicare and Medicaid Services (2013)
eHokenyaku Jiten (保険薬辞典), published by Jihou (じほう), 2013
fUS Hospital charges from HCUP.net (2013), inflated from 2011 US dollars to 2013 US dollars using the medical care component of the Consumer Price Index (US Department of Labor, Bureau of Labor Statistics, 2013)
gJapan costs calculated using the unit costs for drugs used for toxicity management and input from a Japanese physician